Waithaka Mwangi

Dr. Waithaka Mwangi


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLShehnaz Lokhandwala
Shehnaz Lokhandwala
SWSuryakant D Waghela
Suryakant D Waghela
JBJocelyn Bray
Jocelyn Bray
NSNeha Sangewar
Neha Sangewar
CCChloe Charendoff
Chloe Charendoff
WMWaithaka Mwangi
Waithaka Mwangi
African Swine Fever Virus (ASFV) is a high-consequence transboundary animal pathogen that often causes hemorrhagic disease in swine with a case fatality rate close to 100%. Lack of treatment or vaccine for the disease makes it imperative that safe and efficacious vaccines are developed to safeguard the swine industry. In this study, we evaluated the immunogenicity of seven adenovirus-vectored novel ASFV antigens, namely A151R, B119L, B602L, EP402RΔPRR, B438L, K205R and A104R. Immunization of commercial swine with a cocktail of the recombinant adenoviruses formulated in adjuvant primed strong ASFV antigen-specific IgG responses that underwent rapid recall upon boost. Notably, most vaccinees mounted robust IgG responses against all the antigens in the cocktail. Most importantly and relevant to vaccine development, the induced antibodies recognized viral proteins from Georgia 2007/1 ASFV-infected cells by IFA and by western blot analysis. The recombinant adenovirus cocktail also induced ASFV-specific IFN-γ-secreting cells that were recalled upon boosting. Evaluation of local and systemic effects of the recombinant adenovirus cocktail post-priming and post-boosting in the immunized animals showed that the immunogen was well tolerated and no serious negative effects were observed. Taken together, these outcomes showed that the adenovirus-vectored novel ASFV antigen cocktail was capable of safely inducing strong antibody and IFN-γ+ cell responses in commercial swine. The data will be used for selection of antigens for inclusion in a multi-antigen prototype vaccine to be evaluated for protective efficacy.

1 March 2017 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
JMJaime Lopera Madrid
Jaime Lopera Madrid
JOJorge Osorio
Jorge Osorio
YHYongqun He
Yongqun He
ZXZuoshuang Xiang
Zuoshuang Xiang
LALeslie Garry Adams
Leslie Garry Adams
MBMangkey Bounpheng
Mangkey Bounpheng

4 December 2017 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
TDThaddeus C Deiss
Thaddeus C Deiss
MVMelissa Vadnais
Melissa Vadnais
FWFeng Wang
Feng Wang
PCPatricia L Chen
Patricia L Chen
ATAli Torkamani
Ali Torkamani
VSVaughn V Smider
Vaughn V Smider

1 August 2019 in Veterinary Microbiology
Verified
Journal Article
Closed access
SLShehnaz Lokhandwala
Shehnaz Lokhandwala
VPVlad Petrovan
Vlad Petrovan
LPLuca Popescu
Luca Popescu
NSNeha Sangewar
Neha Sangewar
CECatherine Elijah
Catherine Elijah
WMWaithaka Mwangi
Waithaka Mwangi

21 February 2020 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
HSHuldah Sang
Huldah Sang
GMGabrielle Miller
Gabrielle Miller
SLShehnaz Lokhandwala
Shehnaz Lokhandwala
NSNeha Sangewar
Neha Sangewar
SWSuryakant D. Waghela
Suryakant D. Waghela
WMWaithaka Mwangi
Waithaka Mwangi
African swine fever is a major concern due to its negative impact on pork production in affected regions. Due to lack of treatment and a safe vaccine, it has been extremely difficult to control this devastating disease. The mechanisms of virus entry, replication within the host cells, immune evasion mechanisms, correlates of protection, and antigens that are effective at inducing host immune response, are now gradually being identified. This information is required for rational design of novel disease control strategies. Pigs which recover from infection with less virulent ASFV isolates can be protected from challenge with related virulent isolates. This strongly indicates that an effective vaccine against ASFV could be developed. Nonetheless, it is clear that effective immunity depends on both antibody and cellular immune responses. This review paper summarizes the key studies that have evaluated three major approaches for development of African Swine Fever virus vaccines. Recent immunization strategies have involved development and in vivo evaluation of live attenuated virus, and recombinant protein- and DNA-based and virus-vectored subunit vaccine candidates. The limitations of challenge models for evaluating ASFV vaccine candidates are also discussed.

22 September 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
DKDeepak Kumar
Deepak Kumar
FSFrances Shepherd
Frances Shepherd
NSNora L. Springer
Nora L. Springer
WMWaithaka Mwangi
Waithaka Mwangi
DMDouglas Marthaler
Douglas Marthaler
Rotaviruses (RVs) are endemic in swine populations, and all swine herds certainly have a history of RV infection and circulation. Rotavirus A (RVA) and C (RVC) are the most common among all RV species reported in swine. RVA was considered most prevalent and pathogenic in swine; however, RVC has been emerging as a significant cause of enteritis in newborn piglets. RV eradication from swine herds is not practically achievable, hence producers’ mainly focus on minimizing the production impact of RV infections by reducing mortality and diarrhea. Since no intra-uterine passage of immunoglobulins occur in swine during gestation, newborn piglets are highly susceptible to RV infection at birth. Boosting lactogenic immunity in gilts by using vaccines and natural planned exposure (NPE) is currently the only way to prevent RV infections in piglets. RVs are highly diverse and multiple RV species have been reported from swine, which also contributes to the difficulties in preventing RV diarrhea in swine herds. Human RV-gut microbiome studies support a link between microbiome composition and oral RV immunogenicity. Such information is completely lacking for RVs in swine. It is not known how RV infection affects the functionality or structure of gut microbiome in swine. In this review, we provide a detailed overview of genotypic diversity of swine RVs, host-ranges, innate and adaptive immune responses to RVs, homotypic and heterotypic immunity to RVs, current methods used for RV management in swine herds, role of maternal immunity in piglet protection, and prospects of investigating swine gut microbiota in providing immunity against rotaviruses.